GenomeFrontier Therapeutics, Inc. addresses these unmet needs of conventional gene therapy by integrating four platforms: Quantum Nufect™ , Quantum pBac™ , iCellar™ , G-Tailor™ , which improve vector delivery, therapeutic gene integration, cell expansion capacity, and gene design, respectively. Synergistically, these four platforms form the Quantum Engine™ for producing virus-free, gene-modified cells optimal for cell modified gene therapy.
By utilizing Quantum Engine™ to develop gene therapy products for cancer, GenomeFrontier Therapeutics has multiple cell modified gene therapy products undergoing development, including chimeric antigen receptor T (CAR-T) and T cell receptor T (TCR-T). These are live, cell-based “drugs” composed of immune cells that have been genetically modified to greatly enhance targeting and/or fighting capabilities against cancer.